144 related articles for article (PubMed ID: 19470393)
1. Encapsulation of low molecular weight heparins: influence on the anti-Xa/anti-IIa ratio.
Javot L; Lecompte T; Rabiskova M; Maincent P
J Control Release; 2009 Oct; 139(1):8-14. PubMed ID: 19470393
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of a microencapsulated low-molecular-weight heparin to rabbits: anti-Xa and anti-IIa profiles.
Javot L; Sapin A; Scala-Bertola J; Vigneron C; Lecompte T; Maincent P
Thromb Haemost; 2010 Jun; 103(6):1254-67. PubMed ID: 20390227
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
[TBL] [Abstract][Full Text] [Related]
4. Sustained release of low molecular weight heparin from PLGA microspheres prepared by a solid-in-oil-in-water emulsion method.
He J; Zhou Z; Fan Y; Zhou X; Du H
J Microencapsul; 2011; 28(8):763-70. PubMed ID: 22034953
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
[TBL] [Abstract][Full Text] [Related]
6. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
[TBL] [Abstract][Full Text] [Related]
7. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.
Hainer JW; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Leathers T; Leese PT
Thromb Haemost; 2002 May; 87(5):817-23. PubMed ID: 12038783
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin-loaded polymeric nanoparticles: formulation, characterization, and release characteristics.
Hoffart V; Ubrich N; Simonin C; Babak V; Vigneron C; Hoffman M; Lecompte T; Maincent P
Drug Dev Ind Pharm; 2002 Oct; 28(9):1091-9. PubMed ID: 12455468
[TBL] [Abstract][Full Text] [Related]
9. In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities.
Bara L; Mardiguian J; Samama M
Thromb Res; 1990 Feb; 57(4):585-92. PubMed ID: 2158152
[TBL] [Abstract][Full Text] [Related]
10. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation.
Rawat A; Majumder QH; Ahsan F
J Control Release; 2008 Jun; 128(3):224-32. PubMed ID: 18471921
[TBL] [Abstract][Full Text] [Related]
11. Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin.
Yang T; Hussain A; Bai S; Khalil IA; Harashima H; Ahsan F
J Control Release; 2006 Oct; 115(3):289-97. PubMed ID: 17023085
[TBL] [Abstract][Full Text] [Related]
12. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
Siguret V; Pautas E; Février M; Wipff C; Durand-Gasselin B; Laurent M; Andreux JP; d'Urso M; Gaussem P
Thromb Haemost; 2000 Nov; 84(5):800-4. PubMed ID: 11127859
[TBL] [Abstract][Full Text] [Related]
13. Ultrasonic-assisted preparation of a low molecular weight heparin (LMWH) with anticoagulant activity.
Achour O; Bridiau N; Godhbani A; Le Joubioux F; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
Carbohydr Polym; 2013 Sep; 97(2):684-9. PubMed ID: 23911501
[TBL] [Abstract][Full Text] [Related]
14. Bemiparin: pharmacological profile.
Sánchez-Ferrer CF
Drugs; 2010 Dec; 70 Suppl 2():19-23. PubMed ID: 21162606
[TBL] [Abstract][Full Text] [Related]
15. A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats.
Abrial D; Blanc A; Réhailia M; Mismetti P; Bouchut C; Laporte-Simitsidis S; Decousus H; Buisson B
Haemostasis; 2000; 30(5):233-42. PubMed ID: 11251330
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.
Fossler MJ; Barrett JS; Hainer JW; Riddle JG; Ostergaard P; van der Elst E; Sprogel P
Am J Health Syst Pharm; 2001 Sep; 58(17):1614-21. PubMed ID: 11556655
[TBL] [Abstract][Full Text] [Related]
17. Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers.
Hoffart V; Ubrich N; Lamprecht A; Bachelier K; Vigneron C; Lecompte T; Hoffman M; Maincent P
Drug Deliv; 2003; 10(1):1-7. PubMed ID: 12554358
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
Jeske W; Fareed J
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():41-7. PubMed ID: 15085465
[TBL] [Abstract][Full Text] [Related]
19. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit.
Carrie D; Caranobe C; Boneu B
Br J Haematol; 1993 Apr; 83(4):622-6. PubMed ID: 8390849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
